Doloromics is a precision neuropharmaceuticals company. It was set up four years ago, to use newer technologies, particularly in the omics space, to take advantage of different single-cell transcriptomic technologies or proteomic technologies to better understand the progression of neurological diseases like chronic pain.The Doloromics pipeline is built upon a proprietary discovery and validation platform DOLOReS. Jackson Brougher, chief scientific officer and co-founder of Doloromics, is our guest on this week’s Beyond Biotech podcast.00:46-04:41: About Doloromics04:41-07:09: What is chronic pain?07:09-08:30: How challenging is the subjectivity of pain?08:30-11:04: What is nociception?11:04-12:23: The challenges of treating pain12:23-16:35: Is chronic pain a disease?16:35-19:57: What is VX-548?19:57-22:17: Monoclonal antibodies and CGRPs22:17-26:22: How have recent advances in genomic technologies advanced the understanding of pain?26:22-31:03: What is the DOLOReS platform?31:03-32:37: Delivery methods32:37-33:55: Keeping costs low33:55-34:58: Next stepsInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter